این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
International Journal of Hematology-Oncology and Stem Cell Research، جلد ۶، شماره ۳، صفحات ۰-۰
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Autologous Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Lymphoma
چکیده انگلیسی مقاله Introduction: Despite high remission rates in acute lymphoblastic leukemia (ALL) patients after induction chemotherapies, post- remission therapies needed to avoiding relapse. Autologous hematopoietic stem cell transplantation (HSCT) role in the treatment of ALL is still controversial. In this retrospective study, we assessed the outcome of auto- HSCT in the treatment of ALL patients treated in this center. Patients and methods : From March 1991 to December 2005, 25 ALL patients with no suitable donors underwent auto-HSCT. All patients received Endoxan, Cytarabin and Etoposide according to the center- approved protocol for conditioning regimen. The sources of graft were peripheral blood and bone marrow. The patients hospitalized in same special rooms and circumstances. The Kaplan-Meier method was used for the data analysis. Results: The median age of patients was 18 years old (range: 8-54). The majority of patients were male. The mean number of WBC count at diagnosis was 48.5×10 3 /µl. Seventy- two percent of patients received autologous HSCT in CR1. Eighty percent of ALL subtypes were B- lineage. Primary central nervous system involvement at diagnosis time was observed in 16%. The median number of harvested nucleated cells: 4.16×10 8 /kg, MNC: 3.69×10 8 /kg, CD3: 1.52×10 8 /kg and CD34+ cells were 0.07×10 8 /kg of recipient weight. The median time of neutrophil and platelet recovery was 12 (range: 9-37) and 17 (range: 10-74) days, respectively. The median follow-up period for survivors was 12 months (range: 4-110 months). Relapse occurred in 17(68%) of patients. Relapse was the only cause of death in patients. The one-year overall survival (OS) and disease-free survival (DFS) were 46% (SE: 10.2%) and 38% (SE: 9.9%), respectively. Age at transplantation and WBC count at diagnosis time had no significant effect on DFS and OS. Source of stem cells had no significant effect on survival outcome too. Transplantation in first complete remission had the best survival outcome (p =0.01). Conclusion: The role of autologous HSCT in ALL patients who do not have suitable donors is still inferior to chemotherapy alone. Regarding poor results of the current study, further studies on the role of auto- HSCT in specific subtypes of ALL patients is suggested.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله فاطمه غفاری | fatemeh ghaffari
hematology- oncology and stem cell transplantation research center, tehran university of medical sci

سازمان اصلی تایید شده: دانشگاه تهران (Tehran university)

امیر حمدی | amir hamdi
hematology- oncology and stem cell transplantation research center, tehran university of medical sci

سازمان اصلی تایید شده: دانشگاه تهران (Tehran university)

آرش جلالی | arash jalali
hematology- oncology and stem cell transplantation research center, tehran university of medical sci

سازمان اصلی تایید شده: دانشگاه تهران (Tehran university)

لیلا شریفی علی آبادی | leila sharifi aliabadi
hematology- oncology and stem cell transplantation research center, tehran university of medical sci

سازمان اصلی تایید شده: دانشگاه تهران (Tehran university)

محمد جهانی | mohammad jahani
hematology- oncology and stem cell transplantation research center, tehran university of medical sci

سازمان اصلی تایید شده: دانشگاه تهران (Tehran university)

عیسی بایبوردی | eisa baybordi
hematology- oncology and stem cell transplantation research center, tehran university of medical sci

سازمان اصلی تایید شده: دانشگاه تهران (Tehran university)

سید اسدالله موسوی | seyyed asadollah mousavi
hematology- oncology and stem cell transplantation research center, tehran university of medical sci

سازمان اصلی تایید شده: دانشگاه تهران (Tehran university)

مسعود ایروانی | masoud iravani
hematology- oncology and stem cell transplantation research center, tehran university of medical sci

سازمان اصلی تایید شده: دانشگاه تهران (Tehran university)

بابک بهار | babak bahar
hematology- oncology and stem cell transplantation research center, tehran university of medical sci

سازمان اصلی تایید شده: دانشگاه تهران (Tehran university)

اردشیر قوام زاده | ardeshir ghavamzadeh
hematology- oncology and stem cell transplantation research center, tehran university of medical sci

سازمان اصلی تایید شده: دانشگاه تهران (Tehran university)

کامران علی مقدم | kamran alimoghaddam
hematology- oncology and stem cell transplantation research center, tehran university of medical sci

سازمان اصلی تایید شده: دانشگاه تهران (Tehran university)

نشانی اینترنتی http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/338
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Articles
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات